40667-56-9

Upstream product

• 38754-71-1 (3aR,4R,5R,6aS)-4-formyl-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate 
• 40665-86-9 dimethyl 3-(4-chlorophenoxy)-2-oxopropylphosphonate 
• 79171-94-1 Biphenyl-4-carboxylic acid (3aR,4R,5R,6aS)-4-[(E)-4-(4-chloro-phenoxy)-3-oxo-but-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 

Downstream Products

• 79124-67-7 N-(methanesulfonyl)-16-(p-chlorophenoxy)-ω-tetranor-PGE₂-carboxamide 
• 79124-54-2 (3aR,4R,5R,6aS)-4-[(E)-(R)-4-(4-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-ol 
• 444084-22-4 (3aR,4R,5R,6aS)-4-[(E)-(R)-4-(4-Chloro-phenoxy)-3-hydroxy-but-1-enyl]-5-hydroxy-hexahydro-cyclopenta[b]furan-2-one 

Relevant academic research and scientific papers

N-(Methanesulfonyl)-16-phenoxyprostaglandincarboxamides: Tissue-Selective, Uterine Stimulants

In an effort to develop tissue-selective prostaglandin analogues resistant to the metabolic inactivating pathways of the natural materials, hybrid compounds modified both at C-1 with a sulfonimide moiety and in the n-amylcarbinol side chain with substituted phenoxy groups were synthesized and evaluated in a variety of in vitro and in vivo models.Several of these analogues exhibited potent, tissue-selective, uterine stimulant activity, a finding subsequently confirmed in clinical studies with one member of this series, N-(methanesulfonyl)-16-phenoxy-ω-tetranor-PGE2-carboxamide (CP-34089/ZK-57671, sulprostone).